Lumida
/HIMS
⌘K
Hims & Hers Health Inc

Hims & Hers Health Inc

HIMS
$32.84USD-2.49%-0.84 today

MARKET CAP

7.6B

P/E (TTM)

273.7x

FWD P/E

41.8x

DAY RANGE

$32 – $34

52W RANGE

$14
$70

AI Summary

Stalk
Buy NowMedium

HIMS has entered a Lockout Rally marked by long green candles, stacked EMAs, and rising volume driven by forced short covering. Medium-term structure remains bullish after reclaiming key moving averages, and the pattern override permits immediate participation despite short-term extension. Continuation is expected on pullbacks into the EMA cluster.

  • Q1 ’25 revenue jumped 111% YoY to $586 M, driven by new products and subscriber growth
  • 2.6 M subscribers with ~90% retention indicate strong consumer demand and brand loyalty
  • Regulatory scrutiny on peptide and GLP-1 treatments may delay key product rollouts
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Hims & Hers Health, Inc. (NASDAQ: HIMS) operates as a leading telehealth provider, delivering accessible healthcare solutions, focusing primarily on sexual health, weight management, and other wellness categories. The company leverages technology to create personalized healthcare experiences, aiming to streamline traditional healthcare access while expanding its reach both domestically and internationally. Hims & Hers is well-positioned in the telehealth space, with a strong growth trajectory influenced by emerging trends in personalized medicine and preventative care, particularly in the fields involving GLP-1 treatments and hormonal therapies.

Bull says

  • Q1 ’25 revenue jumped 111% YoY to $586 M, driven by new products and subscriber growth
  • 2.6 M subscribers with ~90% retention indicate strong consumer demand and brand loyalty
  • $1.1 B cash reserve supports investments in hormonal therapies and international expansion
  • Guides Q1 ’26 revenue of $680–700 M (+25–28% YoY), underpinning sustained top-line momentum
  • Pivot into branded weight-management and personalized treatments taps high-growth GLP-1 market
  • Positive profitability and liquidity factors suggest efficient capital use and strong trading interest

Bear says

  • Regulatory scrutiny on peptide and GLP-1 treatments may delay key product rollouts
  • Negative earnings yield and weak book-to-price valuation highlight downside risk
  • Incurring ~$33 M in restructuring costs for growth initiatives may pressure near-term margins
  • High volatility and significant short interest could drive further share price declines
  • Intense competition in telehealth and weight-loss markets may compress margins
  • Management’s pivot beyond weight-loss offerings risks diluting core revenue drivers

Investment themes with HIMS

eTailing +0.56%

Online retail and e-commerce platforms

FIGS · LQDT · CVNA
Health Care Providers -0.61%

UNH · CVS · HCA

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-12-2026bullish

Transcript signals

Bull points

  • Today, I'll walk through the initial impact of that decision, early evidence that gives us conviction that it was the right one, our investment priorities moving forward, and finally, how our financial profile builds from here.
  • We believe the pivot that we made to prioritize branded products within our weight loss specialty will be transformational for the HIMS and HERS platform, and early success signals are already emerging.
  • Within weeks of this launch, we are on track to add north of 100,000 new subscribers per month within our weight loss specialty.

Bear points

  • GAAP net income declined to a loss of $92 million in Q1.
Read full transcript analysis ›